Goldman Sachs Starts Acceleron Pharma (XLRN) at Sell

Goldman Sachs initiates coverage on Acceleron Pharma (NASDAQ: XLRN) with a Sell rating and a price target of $20.00.

Analyst Terence Flynn said they expect the stock to be a relative underperformer given the lack of meaningful catalysts this year.

For an analyst ratings summary and ratings history on Acceleron Pharma click here. For more ratings news on Acceleron Pharma click here.

Shares of Acceleron Pharma closed at $30.30 yesterday.

You May Also Be Interested In

• Raymond James Starts SpyGlass Pharma (SGP) at Outperform
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• McGraw Hill (MH) PT Raised to $15 at UBS